Downloads
Abstract
Background: Sorafenib is indicated for first line treatment in advanced hepatocellular carcinoma (HCC) in which curative treatment by surgical resection, liver transplantation or locoregional therapy are not feasible. There is a number of domestic studies with limited sample size. This study was done with 2 aims: Evalue the respones, progression - free survival, overall survival and toxicities of therapies.
Methods: Descriptive study of 30 patients with advanced hepatocellular carcinoma at Da Nang Oncology Hospital from 2019 to 2021.
Results: The disease control rate was 63.4 %, time to disease progression was 5.02 months, overall survival was 7.02 months. The incidence of toxicity was 80%, the majority of those were grade 1 and 2, grade 3 was 30%, not grade 4. Common toxicities were hand food skin reaction (36.7%), fatigue (30%), increased AST/ALT (33.3%). The rate of delay treatment due to toxicity was 23.3%.
Conclusion: Sorafenib is a standard care for first - line treatment for advanced HCC. It was proven to extend overall survival and progression free survival.
References
Bộ Y tế Việt Nam. Hướng dẫn chẩn đoán và điều trị ung thư tế bào gan nguyên phát. Quyết định số 3129/QĐ-BYT 2020; 3-10
Pressiani T, Boni C, Rimassa L et al. Sorafenib in patients with Child - Pugh class A and B advanced hepatocellular carcinoma: aprospective feasibility analysis. Ann Oncol. 2013;24(2): 406-411.
Llovet J.M, Ricci S, Mazzaferro V et al. Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine. 2008; 359(4): 378-390.
Nguyễn Thị Thu Hường. Đánh giá kết quả điêu trị Sorafenb trên BN ung thư gan nguyên phát. Luận án tiến sĩ Y học - Trường Đại học Y Hà Nội. 2020;5-50
Võ Văn Kha. Đánh giá kết quả điều trị ung thư tế bào gan nguyên phát giai đoạn tiến xa bằng Sorafenib. Tạp chí Y dược lâm sàng. 2016; 60.
Lencioni R, Kudo M, Ye S.L et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib: second interim analysis. Int J Clin Pract. 2014; 68(5), 609-617.
Bruix J, Cheng A.L, Meinhardt G et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017; 67(5), 999-1008.
Cheng A L, Kang Y K, Chen Z et al.Efficacy and safety of sorafenib in patients in the Asia - Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double - blind, placebo - controlled trial. Lancet Oncol. 2009; 10(1): 25-34.
Hyuna Sung, Rebecca L, Siegel et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2012; 71(3): 209-249.
Wang P, Tan G, Zhu M et al. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta - analysis. Expert Rev Gastroenterol Hepatol. 2018;12(1): 1-8.
Yeh C.N, Chen M.F, Lee W.C et al. Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol. 2002; 81(4): 195-202.
| Published | 09-08-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 82 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.82.17 | |
| Keywords | Ung thư gan nguyên phát, Sorafenib Hepatocellular carcinoma, sorafenib |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital